{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:39Z","timestamp":1794255879570,"version":"4.9.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Pharmaceutical Company Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03665-6","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:59:04Z","timestamp":1787648344000},"page":"5647-5659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost Per Remission of Vedolizumab Versus Risankizumab for the Treatment of Moderately to Severely Active Crohn\u2019s Disease in Italy"],"prefix":"10.1007","volume":"43","author":[{"given":"Elizabeth","family":"Brook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00eb","family":"Hardern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8745-9889","authenticated-orcid":false,"given":"Jakob","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Viti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Nucit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"9853","key":"3665_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/s0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet. 2012;380(9853):1590\u2013605. https:\/\/doi.org\/10.1016\/s0140-6736(12)60026-9.","journal-title":"Lancet"},{"issue":"1S","key":"3665_CR2","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1097\/meg.0000000000002107","volume":"33","author":"E Crocetti","year":"2021","unstructured":"Crocetti E, Bergamaschi W, Russo AG. Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy. Eur J Gastroenterol Hepatol. 2021;33(1S):e383\u20139. https:\/\/doi.org\/10.1097\/meg.0000000000002107.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"3665_CR3","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.dld.2019.05.017","volume":"51","author":"FS Macaluso","year":"2019","unstructured":"Macaluso FS, Mocci G, Orlando A, Scondotto S, Fantaci G, Antonelli A, et al. Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: a report based on health information systems. Dig Liver Dis. 2019;51(9):1270\u20134. https:\/\/doi.org\/10.1016\/j.dld.2019.05.017.","journal-title":"Dig Liver Dis"},{"issue":"9","key":"3665_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.dld.2014.04.014","volume":"46","author":"R Di Domenicantonio","year":"2014","unstructured":"Di Domenicantonio R, Cappai G, Arc\u00e0 M, Agabiti N, Kohn A, Vernia P, et al. Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems. Dig Liver Dis. 2014;46(9):777\u201382. https:\/\/doi.org\/10.1016\/j.dld.2014.04.014.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"3665_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.dld.2017.09.120","volume":"50","author":"D Valpiani","year":"2018","unstructured":"Valpiani D, Manzi I, Mercuriali M, Giuliani O, Ravaioli A, Colamartini A, et al. A model of an inflammatory bowel disease population-based registry: the Forl\u00ec experience (1993-2013). Dig Liver Dis. 2018;50(1):32\u20136. https:\/\/doi.org\/10.1016\/j.dld.2017.09.120.","journal-title":"Dig Liver Dis"},{"issue":"2","key":"3665_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020641","volume":"12","author":"GP Caviglia","year":"2023","unstructured":"Caviglia GP, Garrone A, Bertolino C, Vanni R, Bretto E, Poshnjari A, et al. Epidemiology of inflammatory bowel diseases: a population study in a healthcare district of North-West Italy. J Clin Med. 2023;12(2):641. https:\/\/doi.org\/10.3390\/jcm12020641.","journal-title":"J Clin Med"},{"issue":"3","key":"3665_CR7","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1756283x15576462","volume":"8","author":"CW Randall","year":"2015","unstructured":"Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, et al. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn\u2019s disease. Ther Adv Gastroenterol. 2015;8(3):143\u201359. https:\/\/doi.org\/10.1177\/1756283x15576462.","journal-title":"Ther Adv Gastroenterol"},{"issue":"10","key":"3665_CR8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2024;18(10):1531\u201355. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae091.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3665_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","volume":"16","author":"S Vermeire","year":"2022","unstructured":"Vermeire S, D\u2019Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial. J Crohns Colitis. 2022;16(1):27\u201338. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab133.","journal-title":"J Crohns Colitis"},{"issue":"8","key":"3665_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1215739.","journal-title":"N Engl J Med"},{"issue":"10340","key":"3665_CR11","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/s0140-6736(22)00467-6","volume":"399","author":"G D'Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015\u201330. https:\/\/doi.org\/10.1016\/s0140-6736(22)00467-6.","journal-title":"Lancet"},{"issue":"10340","key":"3665_CR12","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/s0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031\u201346. https:\/\/doi.org\/10.1016\/s0140-6736(22)00466-4.","journal-title":"Lancet"},{"key":"3665_CR13","unstructured":"Gazzetta Ufficiale, AGENZIA ITALIANA DEL FARMACO. Update to the paper prescription form for Crohn's disease medications for treatment options subsequent to TNF-alpha inhibitors. No. 24A02549. n.118. 2024. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2024-05-22&atto.codiceRedazionale=24A02549&elenco30giorni=true. Accessed 23 January 2026."},{"issue":"9","key":"3665_CR14","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","volume":"15","author":"M Zhao","year":"2021","unstructured":"Zhao M, G\u00f6nczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021;15(9):1573\u201387. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab029.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"3665_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3111\/13696998.2013.775134","volume":"16","author":"JH Lofland","year":"2013","unstructured":"Lofland JH, Mallow P, Rizzo J. Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis. J Med Econ. 2013;16(4):461\u20137. https:\/\/doi.org\/10.3111\/13696998.2013.775134.","journal-title":"J Med Econ"},{"key":"3665_CR16","doi-asserted-by":"publisher","DOI":"10.33393\/grhta.2019.456","author":"M Ruggeri","year":"2019","unstructured":"Ruggeri M, Rolli FR. Cost per response\/remission in biologics available in Italy for the treatment of TNF-\u03b1 inhibitors-na\u00efve patients with ulcerative colitis. Glob Reg Health Technol Assess. 2019;6(1). https:\/\/doi.org\/10.33393\/grhta.2019.456.","journal-title":"Glob Reg Health Technol Assess"},{"issue":"6","key":"3665_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3111\/13696998.2015.1012513","volume":"18","author":"K Toor","year":"2015","unstructured":"Toor K, Druyts E, Jansen JP, Thorlund K. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. J Med Econ. 2015;18(6):437\u201346. https:\/\/doi.org\/10.3111\/13696998.2015.1012513.","journal-title":"J Med Econ"},{"issue":"1","key":"3665_CR18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/13696998.2024.2333683","volume":"27","author":"M Saruta","year":"2024","unstructured":"Saruta M, Kawaguchi I, Ogawa Y, Sanchez Gonzalez Y, Numajiri N, Tang X, et al. Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib. J Med Econ. 2024;27(1):566\u201374. https:\/\/doi.org\/10.1080\/13696998.2024.2333683.","journal-title":"J Med Econ"},{"issue":"1","key":"3665_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33393\/ao.2023.2515","volume":"10","author":"R Ravasio","year":"2023","unstructured":"Ravasio R, Viti R, Roscini AS. Cost per responder for vedolizumab and ustekinumab in Crohn\u2019s disease patients after failure of TNF-\u03b1 inhibitors in Italy. AboutOpen. 2023;10(1):13\u201321. https:\/\/doi.org\/10.33393\/ao.2023.2515.","journal-title":"AboutOpen"},{"key":"3665_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.33393\/grhta.2024.2658","volume":"11","author":"F Caprioli","year":"2024","unstructured":"Caprioli F, Fantini MC, Marando F, Scaduto D, Ravasio R. Cost per number needed to treat (NNT) of upadacitinib in the treatment of bio-exposed patients with moderate to severe active ulcerative colitis. Glob Reg Health Technol Assess. 2024;11:55\u201367. https:\/\/doi.org\/10.33393\/grhta.2024.2658.","journal-title":"Glob Reg Health Technol Assess"},{"issue":"5","key":"3665_CR21","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"issue":"1","key":"3665_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02590-6","volume":"22","author":"V Jairath","year":"2022","unstructured":"Jairath V, Cohen RD, Loftus EV Jr., Candela N, Lasch K, Schultz BG. Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis. BMC Gastroenterol. 2022;22(1):501. https:\/\/doi.org\/10.1186\/s12876-022-02590-6.","journal-title":"BMC Gastroenterol"},{"issue":"Suppl 1","key":"3665_CR23","doi-asserted-by":"publisher","first-page":"i1956","DOI":"10.1093\/ecco-jcc\/jjae190.1235","volume":"19","author":"V Jairath","year":"2025","unstructured":"Jairath V, Dulai PS, Talsma P, Wu JJ, Adsul S. P1061 A matching-adjusted indirect comparison (MAIC) of vedolizumab vs risankizumab in patients with moderately-to-severely active Crohn\u2019s disease. J Crohns Colitis. 2025;19(Suppl 1):i1956\u20138. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.1235.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3665_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10\u201331. https:\/\/doi.org\/10.1016\/j.jval.2021.10.008.","journal-title":"Value Health"},{"key":"3665_CR25","unstructured":"Ministero dell'Economia e delle Finanze. Gazzetta Ufficiale della Repubblica Italiana website. https:\/\/www.gazzettaufficiale.it\/. Accessed 23 January 2025."},{"key":"3665_CR26","unstructured":"Gazzetta Ufficiale. Measures to rationalize public finances. n. 662. 1996. https:\/\/www.gazzettaufficiale.it\/eli\/id\/1996\/12\/28\/096G0686\/sg. Accessed 23 January 2026."},{"key":"3665_CR27","unstructured":"Gazzetta Ufficiale. List of Class A medicines reimbursed by the National Health Service. n. 269. 2006. https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2006-07-07&atto.codiceRedazionale=06A06166. Accessed 23 January 2026."},{"key":"3665_CR28","unstructured":"Takeda Pharmaceuticals (Asia Pacific) Pte Ltd. Entyvio. Prescribing information. 2022. https:\/\/content.takeda.com\/?contenttype=PI&product=ENTY&language=ENG&country=SGP&documentnumber=1. Accessed 23 January 2025."},{"key":"3665_CR29","unstructured":"AbbVie Inc. Skyrizi. Prescribing information. 2025. https:\/\/www.rxabbvie.com\/pdf\/skyrizi_pi.pdf. Accessed 23 January 2025."},{"issue":"5","key":"3665_CR30","doi-asserted-by":"publisher","first-page":"s1234","DOI":"10.1016\/S0016-5085(24)03284-0","volume":"166","author":"RC Ungaro","year":"2024","unstructured":"Ungaro RC, Cross RK, Allegretti JR, Griffith J, Neimark E, Pearson R, et al. Tu1095: risankizumab is associated with lower cost per responder and cost per remitter versus ustekinumab in patients with moderate-to-severe Crohn\u2019s disease: economic analyses from the SEQUENCE trial. Gastroenterology. 2024;166(5):s1234\u20135.","journal-title":"Gastroenterology"},{"issue":"1","key":"3665_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14(1):4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"key":"3665_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231163118","volume":"16","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Danese S, Peyrin-Biroulet L. Can we change the natural course of inflammatory bowel disease? Ther Adv Gastroenterol. 2023;16:17562848231163118. https:\/\/doi.org\/10.1177\/17562848231163118.","journal-title":"Therap Adv Gastroenterol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03665-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03665-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03665-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:03:30Z","timestamp":1794254610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03665-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3665"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03665-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Elizabeth Brook and Chlo\u00eb Hardern are employees of Inizio Ignite Putnam, which received funding from Takeda related to this analysis. Jakob Langer, Raffaella Viti, and Arnaud Nucit are employees of the study sponsor, Takeda, and may hold Takeda stock or stock options.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}